IMMUNEONCO-B(01541): IMC-003/IMM72 approved by the National Medical Products Administration for clinical trials.

IMMUNEONCO-B (01541) announced that the group has obtained approval from the China National Medical Products Administration ("NMPA") for the initiation of IND clinical trials for IMC-003/IMM72 for the treatment of Pulmonary Arterial Hypertension (PAH). IMC-003/IMM72 is a new generation fusion protein of activin receptor IIA-Fc (ActRIIA-Fc) through genetic modification, with higher activity and quality. The group holds global intellectual property rights for IMC-003/IMM72 as well as the rights for development and commercialization.